Hepatic impairment as a risk factor of adverse drug reactions
Open Access
- 15 December 2021
- journal article
- review article
- Published by Consilium Medicum in Consilium Medicum
- Vol. 23 (12) , 939-948
Abstract
There are a lot of clinical variants of hepatic impairment ranging from asymptomatic increase in transaminases to acute liver failure and fulminant hepatitis. Hepatic impairment is a polietiologic syndrome. According to the epidemiological study conducted in the United States (19982008), the main causes of hepatic impairment were paracetamol overdose (46%), idiopathic liver dysfunction (14%), other drugs (excluding paracetamol, 11%), viral hepatitis B (7%), other infectious and non-infectious diseases with liver damage (except for viral hepatitis) 7%, autoimmune hepatitis (5%), ischemic hepatitis (syn. hypoxic hepatitis, liver infarction) 4%, viral hepatitis A (3%) and Wilson's disease (2%). Hepatic impairment have a direct impact on the pharmacokinetics and pharmacodynamics of drugs decreasing clearance, elimination and excretion of drugs. Also Transjugular intrahepatic porto-systemic shunts, which are often used to treat portal hypertension in patients with liver cirrhosis, can significantly reduce the presystemic elimination of drugs, thereby increasing their absorption. Moreover, in patients with liver cirrhosis, concomitant renal dysfunction also requires an adjustment of the dose of drugs. Correction of pharmacotherapy in accordance to pharmacokinetic and pharmacodynamic changes of drugs ingested by patients with impaired liver function will improve the quality of medical care and reduce the risks of adverse drug reactions.Keywords
This publication has 82 references indexed in Scilit:
- Acute liver failureHepatology, 2007
- Cholestasis and Endogenous OpioidsClinical Pharmacokinetics, 2007
- Pharmacokinetics of Opioids in Liver DiseaseClinical Pharmacokinetics, 1999
- Drug Acetylation in Liver DiseaseClinical Pharmacokinetics, 1998
- Pharmacokinetics of Drugs Used in Critically Ill AdultsClinical Pharmacokinetics, 1998
- Pharmacokinetics of Oral Mycophenolate Mofetil in Volunteer Subjects with Varying Degrees of Hepatic Oxidative ImpairmentThe Journal of Clinical Pharmacology, 1996
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver DiseaseClinical Pharmacokinetics, 1995
- Pharmacokinetics of Temafloxacin in Patients with Liver Impairment†Clinical Pharmacokinetics, 1992
- Pharmacokinetics of Midazolam Following Intravenous and Oral Administration in Patients with Chronic Liver Disease and in Healthy SubjectsThe Journal of Clinical Pharmacology, 1989
- Hepatic First-pass Metabolism in Liver DiseaseClinical Pharmacokinetics, 1979